The poor prognosis highlights the urgent need for the development of novel therapeutic strategies for the prevention and treatment of this deadly disease.3 Recent studies showed that hTERT polymorphisms are specifically associated with several subtypes of lung cancer.15 In addition, strong evidence indicates that hTERT and the epidermal growth factor receptor interact in the etiology of lung cancer.15 Consequently, telomerase inhibition-based therapy provides a therapeutic opportunity for lung cancer.14 This evidence concerns the gene EGFR and lung carcinoma.